Participated · Seed · May 2023

Founded in 2021 by Prasanta Sarkar and Rochan Sinha, Newtrace designs and manufactures Voltagen, a proprietary electrode technology for alkaline water electrolyzers used in green hydrogen production. The electrodes are intended as drop-in replacements, enabling electrolyzer manufacturers, green hydrogen project developers and industrial gas companies to boost efficiency, extend system lifetimes and lower hydrogen costs without redesigning existing systems. The company plans to use its latest funding to scale pilot manufacturing, validate its technology with customers and broaden both engineering and manufacturing capabilities. Newtrace targets initial commercial deliveries of Voltagen electrodes within the next 12 months. For the fiscal year ended March 2025, it recorded operating revenue of Rs 1.8 crore while losses widened 73 % to Rs 15.6 crore. The firm positions itself at the intersection of climate tech and industrial hardware, aiming to accelerate the global transition to green hydrogen.

Participated · Seed · Oct 2021

Mestastop Solutions builds a cancer metastasis-focused platform that uses wet-lab biology and predictive analytics to identify and distinguish unique properties of metastasis. Its proprietary platforms include METAssay, METSCAN, and METVivo, with METSCAN positioned as an AI-based tool that characterizes cancer cells using patient data and assay panels. The company plans to scale METSCAN and run proof-of-concept animal model studies to validate approaches for cancer drug discovery and drug repurposing. Mestastop was founded in 2018 and is led by founders Dr. Arnab Roy Chowdhury and Dr. Debabani Roy Chowdhury, supported by a cross-functional team trained in discovery, diagnostics, and AI and by state-of-the-art infrastructure. The company raised Rs 1.3 crore in a seed round in October 2021 to fund platform scaling and PoC studies.

Participated · Seed · Sep 2021

Brainsight Technology, incorporated in 2019, is a healthtech company that provides evidence-based treatment hooks for neurosurgeons, psychiatrists and neurologists, along with private and digital aids for patients and related business activities. The company has focused product offerings for clinical specialists in neurology and psychiatry. It remained at or near pre-revenue until FY23, when operating revenue grew 25.3% to Rs 27.5 lakhs. The firm reported losses of Rs 3.28 crore in the last fiscal year. Brainsight's commercial traction appears limited based on disclosed FY23 numbers, and the company continues to rely on external strategic investments to support its operations and growth. BrainSightAI is a Bengaluru-based deep-tech company offering an MRI-based SaaS platform to improve precision in neurological and psychiatric investigation. The platform aims to enable more precise diagnosis and data-informed treatment planning for neuro-oncological and neuropsychiatric disorders. The company says its technology helps shorten patients' path to recovery by moving from informed estimation to data-assured diagnosis and data-predicted prognosis. BrainSightAI has received ecosystem support, including admission to the GE Edison Accelerator and Dassault Systèmes' 3DEXPERIENCE program. It also won the BIRAC BIG 15 grant from the Government of India in January 2020 to conduct clinical studies on brain-function alteration in dementia. The company plans to use the new capital to further its mission of improving diagnostic and treatment precision.

Participated · Series A · Jul 2021

Skylark Drones operates a technology platform that leverages data gathered from drones to provide actionable business intelligence to enterprises. It offers AI-powered solutions for platform integrations, API access, drone mission execution, and compliance with local airspace regulations. The company serves customers across mining, solar power, real estate, agriculture, and inspection, and maintains offices in the US and India. Skylark was founded in 2015 and previously raised a seed round in 2018. The startup recently completed a $3 million pre-Series A funding round. It plans to use the proceeds to enhance its product offering and to expand further into overseas markets.

Participated · Series A · Feb 2021

PhableCare is an app-based, full-stack chronic disease management platform that connects patients, doctors, pharmacists, device makers, hospitals, e-pharmacies and insurers. Its solution delivers remote consultations, decision-support for doctors, patient engagement, IoT device integration and data-driven disease management. The platform already serves 3M+ patients, 10k+ doctors and 1k+ pharmacists, making it a market leader in India’s chronic-care segment. The company plans to expand to 30M+ Indian households and 100,000+ super-specialist doctors and aims to capture 25% of the market over the next two years. PhableCare will use recent funding to strengthen its full-stack, value-driven chronic-care ecosystem, accelerate customer acquisition and brand building, build new revenue streams, and pursue strategic acquisitions. It has also allocated capital and arranged additional venture-debt to invest in other health-tech startups to expand capacity and capabilities. PhableCare operates a technology platform that creates an ecosystem of patients, doctors, hospitals, health devices, insurance and patient-care service providers to manage chronic diseases. The company provides online doctor consultations and a mobile app that lets patients order medicines, connect health IoT devices (Google Fit, Fitbit, Garmin) and manually or visually upload test results via computer vision. Its platform claims a network of 5,000+ doctors, more than 20,000 booked online consultations, and tracking of over 30 million patients' vitals. The founders say the company aims to reach 5 million patients and 35,000 doctors by the end of the year. PhableCare was founded in 2017 and is led by founders Mukesh Bansal, Sumit Sinha and Prasanth Reddy. To date the startup has raised over $13 million in funding.